Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Terminated Phase 1 Interventional

A Study to Investigate Safety, Tolerability, Pharmacokinetics (PK), Pharmacodynamics (PD), and Immunogenicity of RO7669330 in Participants With Geographic Atrophy (GA) Secondary to Age-related Macular Degeneration (AMD)

ClinicalTrials.gov ID: NCT06961370

Public ClinicalTrials.gov record NCT06961370. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Oct 19, 2026, 10:30 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase I, Multi-center, Multi-part Study to Investigate Safety, Tolerability, PK, PD, and Immunogenicity of RO7669330 Intravitreal Injections in Participants With GA Secondary to AMD: Part 1A: Open-label, MAD; Part 1B: Randomized PD Pilot; Part 2: Masked, Randomized, Active-comparator-controlled

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

The main purpose of this study is to assess the ocular and systemic safety and tolerability of RO7669330 in participants with GA secondary to AMD in at least one eye in Part 1, or both eyes in Part 2, after multiple unilateral intravitreal (IVT) doses.

Study identification

NCT ID
NCT06961370
Recruitment status
Terminated
Study type
Interventional
Phase
Phase 1
Lead sponsor
Hoffmann-La Roche
Industry
Enrollment
27 participants

Conditions and interventions

Eligibility (public fields only)

Age range
55 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Jul 16, 2025 (Actual)
Primary completion
Feb 3, 2026 (Actual)
Completion
Mar 3, 2026 (Actual)
Last update posted
Aug 10, 2026

2025 – 2026

United States locations

U.S. sites
17
U.S. states
10
U.S. cities
17
Facility City State ZIP Site status
Associated Retina Consultants - Phoenix - DocTrials - PPDS Phoenix Arizona 85020-5505 —
Barnet Dulaney Perkins Eye Center Sun City Arizona 85351 —
Retina-Vitreous Associates Medical Group Beverly Hills California 90211 —
Global Research Management Glendale California 91204 —
Retinal Consultants Medical Group Inc - Parkcenter Drive Sacramento California 95825 —
Southeast Retina Center Augusta Georgia 30909 —
Cumberland Valley Retina Consultants PC Hagerstown Maryland 21740 —
Deep Blue Retina Clinical Research Southaven Mississippi 38671 —
The Retina Institute St Louis Missouri 63128 —
Retina Northwest Portland Oregon 97221 —
Erie Retina Research Erie Pennsylvania 16505 —
Charles Retina Institute Germantown Tennessee 38138 —
Tennessee Retina PC Nashville Tennessee 37203 —
Austin Clinical Research, LLC Austin Texas 78750 —
Texas Retina Associates Dallas Texas 75231 —
Retina Consultants of Texas Westover Hills Retina Center San Antonio Texas 78251 —
Retina Consultants of Texas - (The Woodlands) The Woodlands Texas 77384 —

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT06961370, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Aug 10, 2026 · Synced Oct 19, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete public registry record, listed eligibility criteria, and available contact information for NCT06961370 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →